{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T23:44:02Z","timestamp":1787269442187,"version":"build-2736575974"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,8]],"date-time":"2021-10-08T00:00:00Z","timestamp":1633651200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,8]],"date-time":"2021-10-08T00:00:00Z","timestamp":1633651200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Amgen Korea"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>To estimate the risk of recurrent cardiovascular events in a real-world population of very high-risk Korean patients with prior myocardial infarction (MI), ischemic stroke (IS), or symptomatic peripheral artery disease (sPAD), similar to the Further cardiovascular OUtcomes Research with proprotein convertase subtilisin\u2013kexin type 9 Inhibition in subjects with Elevated Risk (FOURIER) trial population.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This retrospective study used the Asan Medical Center Heart Registry database built on electronic medical records (EMR) from 2000 to 2016. Patients with a history of clinically evident atherosclerotic cardiovascular disease (ASCVD) with multiple risk factors were followed up for 3\u00a0years. The primary endpoint was a composite of MI, stroke, hospitalization for unstable angina, coronary revascularization, and all-cause mortality.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Among 15,820 patients, the 3-year cumulative incidence of the composite primary endpoint was 15.3% and the 3-year incidence rate was 5.7 (95% CI 5.5\u20135.9) per 100 person-years. At individual endpoints, the rates of deaths, MI, and IS were 0.4 (0.3\u20130.4), 0.9 (0.8\u20130.9), and 0.8 (0.7\u20130.9), respectively. The risk of the primary endpoint did not differ significantly between recipients of different intensities of statin therapy. Low-density lipoprotein cholesterol (LDL-C) goals were only achieved in 24.4% of patients during the first year of follow-up.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>By analyzing EMR data representing routine practice in Korea, we found that patients with very high-risk ASCVD were at substantial risk of further cardiovascular events in 3\u00a0years. Given the observed risk of recurrent events with suboptimal lipid management by statin, additional treatment to control LDL-C might be necessary to reduce the burden of further cardiovascular events for very high-risk ASCVD patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10557-021-07255-2","type":"journal-article","created":{"date-parts":[[2021,10,8]],"date-time":"2021-10-08T23:14:47Z","timestamp":1633734887000},"page":"129-140","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Cardiovascular Event Rates in Statin-Treated Korean Patients with Cardiovascular Disease: Estimates from a Real-World Population Using Electronic Medical Record Data"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6857-8632","authenticated-orcid":false,"given":"Osung","family":"Kwon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1660-8101","authenticated-orcid":false,"given":"Wonjun","family":"Na","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7235-8675","authenticated-orcid":false,"given":"Jaehee","family":"Hur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4193-0891","authenticated-orcid":false,"given":"Ju Hyeon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6808-5149","authenticated-orcid":false,"given":"Tae Joon","family":"Jun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0396-2112","authenticated-orcid":false,"given":"Hee Jun","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3590-5673","authenticated-orcid":false,"given":"Hojoon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3610-486X","authenticated-orcid":false,"given":"Young-Hak","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,8]]},"reference":[{"issue":"10100","key":"7255_CR1","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1016\/S0140-6736(17)32152-9","volume":"390","author":"GBD 2016 Causes of Death Collaborators","year":"2017","unstructured":"GBD 2016 Causes of Death Collaborators. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390(10100):1151\u2013210.","journal-title":"Lancet"},{"issue":"3","key":"7255_CR2","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1002\/clc.23160","volume":"42","author":"S Li","year":"2019","unstructured":"Li S, Peng Y, Wang X, et al. Cardiovascular events and death after myocardial infarction or ischemic stroke in an older Medicare population. Clin Cardiol. 2019;42(3):391\u20139.","journal-title":"Clin Cardiol"},{"issue":"4","key":"7255_CR3","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1161\/CIRCOUTCOMES.111.964700","volume":"5","author":"K Smolina","year":"2012","unstructured":"Smolina K, Wright FL, Rayner M, Goldacre MJ. Long-term survival and recurrence after acute myocardial infarction in England, 2004 to 2010. Circ Cardiovasc Qual Outcomes. 2012;5(4):532\u201340.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"6","key":"7255_CR4","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1161\/01.STR.0000072985.24967.7F","volume":"34","author":"T Hillen","year":"2003","unstructured":"Hillen T, Coshall C, Tilling K, Rudd AG, McGovern R, Wolfe CD, South London Stroke Register. Cause of stroke recurrence is multifactorial: patterns, risk factors, and outcomes of stroke recurrence in the South London Stroke Register. Stroke. 2003;34(6):1457\u201363.","journal-title":"Stroke"},{"issue":"8","key":"7255_CR5","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/clc.22428","volume":"38","author":"RS Punekar","year":"2015","unstructured":"Punekar RS, Fox KM, Richhariya A, et al. Burden of first and recurrent cardiovascular events among patients with hyperlipidemia. Clin Cardiol. 2015;38(8):483\u201391.","journal-title":"Clin Cardiol"},{"issue":"5","key":"7255_CR6","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/nrcardio.2014.26","volume":"11","author":"ND Wong","year":"2014","unstructured":"Wong ND. Epidemiological studies of CHD and the evolution of preventive cardiology. Nat Rev Cardiol. 2014;11(5):276\u201389.","journal-title":"Nat Rev Cardiol"},{"issue":"1","key":"7255_CR7","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.pop.2012.11.003","volume":"40","author":"RH Nelson","year":"2013","unstructured":"Nelson RH. Hyperlipidemia as a risk factor for cardiovascular disease. Prim Care. 2013;40(1):195\u2013211.","journal-title":"Prim Care"},{"issue":"Suppl 2","key":"7255_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4158\/EP171764.APPGL","volume":"23","author":"PS Jellinger","year":"2017","unstructured":"Jellinger PS, Handelsman Y, Rosenblit PD, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease. Endocr Pract. 2017;23(Suppl 2):1\u201387.","journal-title":"Endocr Pract"},{"issue":"25","key":"7255_CR9","doi-asserted-by":"publisher","first-page":"3143","DOI":"10.1161\/circ.106.25.3143","volume":"106","author":"National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)","year":"2002","unstructured":"National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143\u2013421.","journal-title":"Circulation"},{"issue":"32","key":"7255_CR10","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","volume":"38","author":"BA Ference","year":"2017","unstructured":"Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459\u201372.","journal-title":"Eur Heart J"},{"issue":"10059","key":"7255_CR11","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.1016\/S0140-6736(16)31357-5","volume":"388","author":"R Collins","year":"2016","unstructured":"Collins R, Reith C, Emberson J, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016;388(10059):2532\u201361.","journal-title":"Lancet"},{"issue":"14","key":"7255_CR12","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1093\/eurheartj\/ehx566","volume":"39","author":"KC Koskinas","year":"2018","unstructured":"Koskinas KC, Siontis GCM, Piccolo R, et al. Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials. Eur Heart J. 2018;39(14):1172\u201380.","journal-title":"Eur Heart J"},{"issue":"18","key":"7255_CR13","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Giugliano RP, Keech AC, FOURIER Steering Committee and Investigators, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713\u201322.","journal-title":"N Engl J Med"},{"issue":"2","key":"7255_CR14","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s10557-019-06864-2","volume":"33","author":"LD Colantonio","year":"2019","unstructured":"Colantonio LD, Monda KL, Rosenson RS, et al. Characteristics and cardiovascular disease event rates among African Americans and whites who meet the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk (FOURIER) trial inclusion criteria. Cardiovasc Drugs Ther. 2019;33(2):189\u201399.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"3","key":"7255_CR15","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1093\/ehjqcco\/qcy058","volume":"5","author":"M Lindh","year":"2019","unstructured":"Lindh M, Banefelt J, Fox KM, et al. Cardiovascular event rates in a high atherosclerotic cardiovascular disease risk population: estimates from Swedish population-based register data. Eur Heart J Qual Care Clin Outcomes. 2019;5(3):225\u201332.","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"issue":"6","key":"7255_CR16","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1080\/13696998.2017.1284078","volume":"20","author":"PP Toth","year":"2017","unstructured":"Toth PP, Danese M, Villa G, et al. Estimated burden of cardiovascular disease and value-based price range for evolocumab in a high-risk, secondary-prevention population in the US payer context. J Med Econ. 2017;20(6):555\u201364.","journal-title":"J Med Econ"},{"issue":"2","key":"7255_CR17","doi-asserted-by":"publisher","first-page":"109","DOI":"10.4258\/hir.2014.20.2.109","volume":"20","author":"SY Shin","year":"2014","unstructured":"Shin SY, Kim WS, Lee JH. Characteristics desired in clinical data warehouse for biomedical research. Healthc Inform Res. 2014;20(2):109\u201316.","journal-title":"Healthc Inform Res"},{"issue":"1","key":"7255_CR18","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s12911-021-01392-2","volume":"21","author":"I Ahn","year":"2021","unstructured":"Ahn I, Na W, Kwon O, et al. CardioNet: a manually curated database for artificial intelligence-based research on cardiovascular diseases. BMC Med Inform Decis Mak. 2021;21(1):29.","journal-title":"BMC Med Inform Decis Mak"},{"issue":"3","key":"7255_CR19","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.amjcard.2006.08.051","volume":"99","author":"JK Liao","year":"2007","unstructured":"Liao JK. Safety and efficacy of statins in Asians. Am J Cardiol. 2007;99(3):410\u20134.","journal-title":"Am J Cardiol"},{"issue":"4","key":"7255_CR20","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1111\/bcpt.12765","volume":"121","author":"HS Kim","year":"2017","unstructured":"Kim HS, Lee H, Lee SH, et al. Use of moderate-intensity statins for low-density lipoprotein cholesterol level above 190 mg\/dL at baseline in Koreans. Basic Clin Pharmacol Toxicol. 2017;121(4):272\u20138.","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"18","key":"7255_CR21","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1177\/2047487318806359","volume":"25","author":"J Ferrieres","year":"2018","unstructured":"Ferrieres J, De Ferrari GM, Hermans MP, et al. Predictors of LDL-cholesterol target value attainment differ in acute and chronic coronary heart disease patients: results from DYSIS II Europe. Eur J Prev Cardiol. 2018;25(18):1966\u201376.","journal-title":"Eur J Prev Cardiol"},{"issue":"6","key":"7255_CR22","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1111\/jcpt.12447","volume":"41","author":"NC Tan","year":"2016","unstructured":"Tan NC, Goh CC, Goh SC, Koh YL, Koh KH. The effect of the intensity of lipid-lowering medications on the LDL cholesterol treatment goals of Asian patients with dyslipidaemia in primary care. J Clin Pharm Ther. 2016;41(6):677\u201383.","journal-title":"J Clin Pharm Ther"},{"key":"7255_CR23","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ahj.2019.05.009","volume":"214","author":"MG Nanna","year":"2019","unstructured":"Nanna MG, Navar AM, Wang TY, et al. Practice-level variation in statin use and low-density lipoprotein cholesterol control in the United States: results from the Patient and Provider Assessment of Lipid Management (PALM) registry. Am Heart J. 2019;214:113\u201324.","journal-title":"Am Heart J"},{"issue":"5","key":"7255_CR24","doi-asserted-by":"publisher","first-page":"567","DOI":"10.5551\/jat.31179","volume":"23","author":"CE Chiang","year":"2016","unstructured":"Chiang CE, Ferri\u00e8res J, Gotcheva NN, et al. Suboptimal control of lipid levels: results from 29 countries participating in the centralized pan-regional surveys on the undertreatment of hypercholesterolaemia (CEPHEUS). J Atheroscler Thromb. 2016;23(5):567\u201387.","journal-title":"J Atheroscler Thromb"},{"issue":"4","key":"7255_CR25","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1002\/jhm.102","volume":"1","author":"B Ovbiagele","year":"2006","unstructured":"Ovbiagele B, Hills NK, Saver JL, Johnston SC,\u00a0CASPR Investigators. Lipid assessment and treatment patterns in hospitalized TIA and ischemic stroke patients. J Hosp Med. 2006;1(4):214\u201320.","journal-title":"J Hosp Med"},{"issue":"11","key":"7255_CR26","doi-asserted-by":"publisher","first-page":"3343","DOI":"10.1161\/STROKEAHA.114.006736","volume":"45","author":"G Saposnik","year":"2014","unstructured":"Saposnik G, Fonarow GC, Pan W, AHA Get-with-the-Guidelines Stroke, et al. Guideline-directed low-density lipoprotein management in high-risk patients with ischemic stroke: findings from Get with the Guidelines-Stroke 2003 to 2012. Stroke. 2014;45(11):3343\u201351.","journal-title":"Stroke"},{"issue":"1","key":"7255_CR27","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1161\/01.STR.0000195127.12990.43","volume":"37","author":"AJ Mullard","year":"2006","unstructured":"Mullard AJ, Reeves MJ, Jacobs BS, Paul Coverdell National Acute Stroke Registry Michigan Prototype Investigators, et al. Lipid testing and lipid-lowering therapy in hospitalized ischemic stroke and transient ischemic attack patients: results from a statewide stroke registry. Stroke. 2006;37(1):44\u20139.","journal-title":"Stroke"},{"issue":"3","key":"7255_CR28","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1007\/s11845-018-1739-8","volume":"187","author":"D N\u00ed Chr\u00f3in\u00edn","year":"2018","unstructured":"N\u00ed Chr\u00f3in\u00edn D, N\u00ed Chr\u00f3in\u00edn C, Akijian L, et al. Suboptimal lipid management before and after ischaemic stroke and TIA-the North Dublin Population Stroke Study. Ir J Med Sci. 2018;187(3):739\u201346.","journal-title":"Ir J Med Sci"},{"key":"7255_CR29","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.atherosclerosis.2017.08.013","volume":"266","author":"AK Gitt","year":"2017","unstructured":"Gitt AK, Lautsch D, Ferri\u00e8res J, et al. Cholesterol target value attainment and lipid-lowering therapy in patients with stable or acute coronary heart disease: results from the Dyslipidemia International Study II. Atherosclerosis. 2017;266:158\u201366.","journal-title":"Atherosclerosis"},{"issue":"5","key":"7255_CR30","first-page":"13","volume":"19","author":"YS Yang","year":"2020","unstructured":"Yang YS, Yang BR, Kim MS, et al. Low-density lipoprotein cholesterol goal attainment rates in high-risk patients with cardiovascular diseases and diabetes mellitus in Korea: a retrospective cohort study. Lipids Health Dis. 2020;19(5):13.","journal-title":"Lipids Health Dis"}],"updated-by":[{"DOI":"10.1007\/s10557-021-07292-x","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T00:00:00Z","timestamp":1637193600000}}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-021-07255-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-021-07255-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-021-07255-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T09:13:26Z","timestamp":1673428406000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-021-07255-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,8]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["7255"],"URL":"https:\/\/doi.org\/10.1007\/s10557-021-07255-2","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s10557-021-07292-x","asserted-by":"object"}]},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,8]]},"assertion":[{"value":"3 September 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2021","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s10557-021-07292-x","URL":"https:\/\/doi.org\/10.1007\/s10557-021-07292-x","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"For this retrospective observational study, collection of de-identified data from the AMC Heart Registry based on implied consent was approved by the Asan Medical Center institutional review board. De-identification of data was performed in accordance with the health insurance portability and accountability act in Korea.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval\/Research Involving Human Participants"}},{"value":"Implied consent was provided due to participation in the AMC Heart Registry.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Hojoon Lee reports employment by Amgen Korea. All other authors have nothing to disclose.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}